Analyst John Newman works at CANACCORD and is covering the the Healthcare sector with 248 price targets and ratings documented since 2014 spanning on 22 stocks.
John Newman's average stock forecast success ratio is 30.9% with an average time for price targets to be met of 114.18 days.
Most recent stock forecast was given on IMGN, ImmunoGen, Inc at 05-Jun-2023.
Analyst best performing recommendations are on ACLX.
The best stock recommendation documented was for ACLX at 4/19/2023. The price target of $40 was fulfilled within 5 days with a profit of $4.74 (13.44%) receiving and performance score of 26.89.
Average potential price target upside
Currently, out of the existing stock ratings of John Newman - 4 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Sell
32
$5.94 (22.79%)
16
6 months 20 days ago
4/6 (66.67%)
$-1.5 (-5.74%)
152
Buy
37
$10.94 (41.98%)
33
10 months 1 days ago
8/14 (57.14%)
$11.89 (32.81%)
54
Buy
96
$69.94 (268.38%)
96
1 years 3 months 3 days ago
0/6 (0%)
$53.67 (151.78%)
Buy
67
$40.94 (157.10%)
61
1 years 3 months 12 days ago
5/8 (62.5%)
$23.34 (53.31%)
241
Buy
44
$17.94 (68.84%)
52
1 years 3 months 21 days ago
8/13 (61.54%)
$15.7 (35.07%)
175
